Aquilon Pharma Overview

  • Status
  • Private

  • Employees
  • 14

Employees
  • Latest Deal Type
  • Series B

  • (Cancelled)
  • Investors
  • 5

Aquilon Pharma General Information

Description

Operator of a pharmaceutical firm intended to develop drugs for the treatment of pulmonary diseases. The company's firm focuses on the development of drugs for the treatment of respiratory disorders and enhances both the lung deposition and the pharmacology of existing drugs for asthma and chronic obstructive pulmonary disease (COPD), enabling patients to get efficient inhalation drugs for respiratory problems.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • Quai de la Boverie 59
  • Walloon Region
  • 4020 Liege
  • Belgium
+32 04 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquilon Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) Cancelled Generating Revenue
3. Early Stage VC 12-Dec-2018 00.00 00.000 Completed Generating Revenue
2. Angel (individual) 26-Oct-2015 $388K $388K 00000 Completed Generating Revenue
1. Accelerator/Incubator 14-Nov-2011 Completed Generating Revenue
To view Aquilon Pharma’s complete valuation and funding history, request access »

Aquilon Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 00000.00 00000.00 00 00000.00 00.000
To view Aquilon Pharma’s complete cap table history, request access »

Aquilon Pharma Patents

Aquilon Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4003320-A1 Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases Pending 10-Sep-2019 0000000000
CA-3150551-A1 Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases Pending 10-Sep-2019 0000000000
EP-3993810-A1 Inhalable composition comprising cyclodextrin for use in the treatment of nasal inflammations Pending 01-Jul-2019 A61K31/724

Aquilon Pharma Executive Team (10)

Name Title Board Seat Contact Info
Paul Maes Co-Founder, Chief Executive Officer & Chairman
Antoine Carlhian Chief Financial Officer
Damien Thiéry Chief Operating Officer & Chief Corporate Development Officer
Pascal Alexis Financial Operations
Jean-Louis Poplavsky MD Senior Medical Advisor
You’re viewing 5 of 10 executive team members. Get the full list »

Aquilon Pharma Board Members (3)

Name Representing Role Since
Didier Cataldo Aquilon Pharma Co-Founder, Chairman of Scientific Committee, Administrator & Board Member 000 0000
Frank Pieters Aquilon Pharma Chairman of the Executive Team BD & Strategy and Board Member 000 0000
Paul Maes Aquilon Pharma Co-Founder, Chief Executive Officer & Chairman 000 0000
To view Aquilon Pharma’s complete board members history, request access »

Aquilon Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aquilon Pharma Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Noshaq Venture Capital Minority 000 0000 000000 0
SambrInvest Venture Capital Minority 000 0000 000000 0
Scale Investment Funds Venture Capital Minority 000 0000 000000 0
Be Angels Angel Group Minority 000 0000 000000 0
WBC Ventures Accelerator/Incubator 000 0000 000000 0
To view Aquilon Pharma’s complete investors history, request access »